covid19

his study is a sub-study to the parent D2eft study, which is a multi-site, open label, randomized clinical trial. D2eft is evaluating the clinical, immunologic, virologic and quality of life measures of enrolled study participants randomized to three different  combination regimens of 2nd line ART in adult HIV patients who have failed 1st line treatment. With the advent of the Covid-19 pandemic the COHIVE study was developed. It pools together the sample sizes of 5 parent protocols, namely D2eft, ADVANCE, DolPHIN2, NAMSAL and WRHI 052 to characterize the clinical features and course of symptomatic COVID-19 in people living with HIV (PLWH) described overall and by HIV and comorbid factors including pregnancy.

The ITAC (Inpatient Treatment with Anticoronavirus Immunoglobulin) study is an International multicenter, adaptive, randomized double-blind, placebo- controlled trial of the safety, tolerability and efficacy of anti-Coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult hospitalized patients at onset of clinical progression of COVID-19. This trial will involve sites around the world strategically chosen to ensure rapid enrollment and will evaluate the use of hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo, when added to Remdesivir as the standard of care, for preventing further disease progression and mortality related to COVID-19